Showing results (21-30 of 65) with videos related to
Sort By:
Pageof 7
Pediatric Blood & Cancer|December 20, 2011
NK cell immunotherapy for high-risk neuroblastoma relapse after haploidentical HSCTJustyna Kanold, Catherine Paillard, Andrei Tchirkov, et al.Journal for Immunotherapy of Cancer|May 3, 2024
Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumorsLaurent Mathiot, David Combarel, Justin Cagnat, et al.Journal for Immunotherapy of Cancer|November 10, 2023
Local and distant response to intratumoral immunotherapy assessed by immunoPET in miceLouis Meyblum, Céline Chevaleyre, Sandrine Susini, et al.Journal for Immunotherapy of Cancer|September 30, 2022
Artificial intelligence and radiomics: fundamentals, applications, and challenges in immunotherapyLaurent Dercle, Jeremy McGale, Shawn Sun, et al.Journal for Immunotherapy of Cancer|September 27, 2018
Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor-related protein agonist AMG 228 in patients with advanced solid tumorsBen Tran, Richard D Carvajal, Aurelien Marabelle, et al.European Journal of Cancer (Oxford, England : 1990)|September 25, 2021
Current strategies for intratumoural immunotherapy - Beyond immune checkpoint inhibitionJianda Yuan, Anuradha Khilnani, Joshua Brody, et al.Transfusion|September 4, 2007
Photopheresis in pediatric graft-versus-host disease after allogeneic marrow transplantation: clinical practice guidelines based on field experience and review of the literatureJustyna Kanold, Etienne Merlin, Pascale Halle, et al.Journal for Immunotherapy of Cancer|February 8, 2022
CD8+PD-1+ to CD4+PD-1+ ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockersBoris Duchemann, Marie Naigeon, Edouard Auclin, et al.The British Journal of Radiology|September 8, 2022
Synergizing liver systemic treatments with interventional oncology: friend or foe?Raphaël Jost, Nael Al-Shatti, Mario Ghosn, et al.European Journal of Cancer (Oxford, England : 1990)|May 13, 2023
Profile and outcome of cancer patients enrolled in contemporary phase I trialsEmily Alouani, Anas Gazzah, Sandrine Mercier, et al.Pageof 7